Mifoglame (Sitagliptin)

Sitagliptin, the active ingredient in Mifoglame, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Mifoglame as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. All batches meet EU pharmacopeial standards and are shipped under controlled conditions. The company maintains rigorous quality assurance and traceability throughout the supply chain.

Mifoglame (sitagliptin) is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels as a single oral agent. - Type 2 diabetes mellitus (combination therapy): enhances overall glycaemic control when added to metformin or other oral antihyperglycaemics. - Type 2 diabetes mellitus (renal‑impairment subgroups): may be used without dose adjustment in patients with mild to moderate renal impairment, providing a convenient option for this population.

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as sore throat or nasal congestion. - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: usually transient and mild. - Gastrointestinal discomfort: includes nausea, dyspepsia or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Bullous pemphigoid: autoimmune skin blistering disorder. - Hepatic enzyme elevation: significant increase in liver transaminases.

When prescribing sitagliptin, clinicians should consider several safety aspects. - Renal function: assess before initiating and monitor periodically, especially in patients with chronic kidney disease. - Hepatic impairment: use with caution in moderate to severe liver disease and monitor liver enzymes. - History of pancreatitis: avoid in patients with prior episodes of pancreatitis. - Hypersensitivity: discontinue immediately if signs of severe allergic reaction appear. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sitagliptin can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce sitagliptin exposure. - Concomitant insulin therapy: increases risk of hypoglycaemia. - GLP‑1 receptor agonists: additive glucose‑lowering effect may lead to excessive hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may raise serum creatinine; monitor renal function. - Warfarin: occasional reports of altered INR; check coagulation parameters. - ACE inhibitors: monitor for hypotension when combined with other glucose‑lowering agents.